The goal of this clinical trial is to learn if budesonide works to prevent bronchopulmonary dysplasia in newborn less than 32 weeks gestational age or birth weight less than 1500 g with respiratory distress syndrome who needs surfactants. Does budesonide lower the incidence of bronchopulmonary dysplasia? What medical problems do participants have after given budesonide? Researchers will compare intratracheal budesonide and surfactant to intratracheal surfactant only to see if budesonide works to prevent bronchopumonary dysplasia.
Participants will:
Given intratracheal budesonide and surfactant and followed up until 36 weeks of post menstrual age to determine whether they have bronchopulmonary dysplasia or not
Inclusion Criteria:
Exclusion Criteria:
- chromosom abnormality
This was a single-blind study. The intervention team was aware of the treatment allocation owing to preparation requirements, whereas the attending pediatricians and clinical staff responsible for patient management and outcome assessment were blinded to the group assignment.
budesonide 25 mg/kgBW administered with beractant 100 mg/kgBW intratracheal
Control group, will received surfactant intratracheal Control group will receive 100 mg/kgBB intratracheal within 48 hours
Jakarta, DKI Jakarta 10430, Indonesia
Budesonia + Intratracheal Surfactant in Incidence of Bronchopulmonary Dysplasia
Intratracheal Budesonide/Surfactant Prevents BPD
The Budesonide in Babies (BiB) Trial
Efficacy and Safety of Inhaled Budesonide in Very Preterm Infants at Risk for Bronchopulmonary Dysplasia
Intratracheal Budesonide With Surfactant to Prevent Bronchopulmmonary Dysplasia.
Pilot Study of Topical Steroid for Prevention of Chronic Lung Disease in Extremely Premature Infants.
Intra-tracheal Instillation of Budesonide to Prevent Chronic Lung Disease
Inhaled Budesonide for Non-ventilated Infants at High Risk of Bronchopulmonary Dysplasia: the i-BUD Pilot Study